These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 17931528)

  • 1. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
    Regan DG; Philp DJ; Hocking JS; Law MG
    Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
    Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
    Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
    Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
    Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
    Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
    Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
    Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
    Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
    Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
    Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
    BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
    Bonanni P; Gabutti G; Demarteau N; Boccalini S; La Torre G
    BMC Infect Dis; 2015 Sep; 15():377. PubMed ID: 26381489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.